To review the existing literature on the efficacy and tolerability of antipsychotics for adolescent psychosis. The review focuses in particular on literature regarding adverse effects that are thought to have an increased incidence in young patients and on the possible neurobiological bases for such differential sensitivity.
Method:
Pertinent studies were sought using Medline searches, supplemented by selected bibliographies, and reviewed.
Results:
There is a relative paucity of research in this area; in particular, well-controlled trials are lacking. The existing literature suggests fairly good efficacy of both typical and atypical antipsychotics in the treatment of psychotic disorders in children and adolescents. However, the incidence of certain side effects, particularly extrapyramidal symptoms (EPS), is found to be higher in young patients compared with adults. Positron emission tomography (PET) receptor studies in adults have demonstrated that the incidence of EPS is related to dose-dependent dopamine type-2 (D2) receptor occupancy and that there is a significant relationship between the number of these receptors and age.
Conclusions:
Improved tolerability is leading to the increasing use of atypical antipsychotics for adolescent patients, though these new drugs do have specific adverse effects of their own. There is a need for more controlled studies of atypical antipsychotics in children and adolescents. In particular, dose-finding studies are needed to determine the optimal dose range to produce the greatest improvement with the least side effects for each of these new drugs.
McClellanJWerryJ.Practice parameters for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry1994;33:616–35.
2.
McClellanJMWerryJS. Schizophrenia. Psychiatr Clin North Am1992;15:131–8.
3.
SeemanPLeeTChau-WongMWongK.Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature1976;261:717–9.
4.
PoolDBloomWMielkeDHRonigerJJJrGallantDM. A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients. Current Therapeutic Research1976;19:99–104.
5.
RealmutoGMEricksonWDYellinAMHopwoodJHGreenbergLM. Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. Am J Psychiatry1984;141:440–2.
6.
SpencerEKKafantarisVPadron-GayolMVRosenbergCRCampbellM.Haloperidol in schizophrenic children: Early findings from a study in progress. Psychopharmacol Bull1992;28:183–6.
7.
SpencerEKCampbellM.Children with schizophrenia: Diagnosis, phenomenology, and pharmacotherapy. Schizophr Bull1994;20:713–25.
8.
MasiG.Atypical neuroleptics in the treatment of early onset schizophrenia. Panminerva Med1997;39:215–21.
9.
SiefenGRemschmidtH.Results of treatment with clozapine in schizophrenic adolescents. Z Kinder Jugenpsychiatr1986;14:245–57.
10.
BirmaherBBakerRKapurSQuintanaHGanguliR.Clozapine for the treatment of adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry1992;31:160–4.
11.
RemschmidtHSchulzEMartinPDM. An open trial of clozapine in thirty-six adolescents with schizophrenia. J Child Adolesc Psychopharmacol1994;4:31–41.
12.
MozesTTorenPChemauzanNMesterRYoran-HegeshRBlumensohnR, and others. Clozapine treatment in very early onset schizophrenia. J Am Acad Child Adolesc Psychiatry1994;33:65–70.
13.
JacobsenLKWalkerMCEdwardsJEChappellPBWoolstonJL. Clozapine in the treatment of a young adolescent with schizophrenia. J Am Acad Child Adolesc Psychiatry1994;33:645–50.
14.
TowbinKEDykensEMPuglieseRG. Clozapine for early developmental delays with childhood-onset schizophrenia: Protocol and 15–month outcome. J Am Acad Child Adolesc Psychiatry1994;33:651–7.
15.
KumraSFrazierJAJacobsenLKMcKennaKGordonCTLenaneMC, and others. Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry1996;53:1090–7.
16.
FrazierJAGordonCTMcKennaKLenaneMCJihDRapoportJL. An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry1994;33:658–63.
17.
TuretzMMozesTTorenPChemauzanNYoran-HegeshRMesterR, and others. An open trial of clozapine in neuroleptic-resistant childhood-onset schizophrenia. Br J Psychiatry1997;170:507–10.
18.
CozzaSJEdisonDL. Risperidone in adolescents [letter]. J Am Acad Child Adolesc Psychiatry1994;33:1211.
19.
QuintanaHKeshavanM.Case study: Risperidone in children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry1995;34:1292–6.
20.
MandokiMW. Risperidone treatment of children and adolescents: Increased risk of extrapyramidal side effects?J Child Adolesc Psychopharmacol1995;5:49–67.
21.
SimeonJGCarreyNJWigginsDMMilinRPHosenbocusSN. Risperidone effects in treatment-resistant adolescents: Preliminary case reports. J Child Adolesc Psychopharmacol1995;5:69–79.
22.
EdelmanRJ. Risperidone side effects. J Am Acad Child Adolesc Psychiatry1996;35:4–5.
23.
ZuddasAPintorMCianchettiC.Risperidone for negative symptoms [letter], J Am Acad Child Adolesc Psychiatry1996;35:838–9.
24.
DhosscheDPetridesG.Negative symptoms or catatonia? [letter]. J Am Acad Child Adolesc Psychiatry1997;36:302–3.
25.
GrcevichSJFindlingRLRowaneWAFriedmanLSchulzSC. Risperidone in the treatment of children and adolescents with schizophrenia: A retrospective study. J Child Adolesc Psychopharmacol1996;6:251–7.
26.
ArmenterosJLWhitakerAHWeliksonMStedgeDJGormanJ.Risperidone in adolescents with schizophrenia: An open pilot study. J Am Acad Child Adolesc Psychiatry1997;36:694–700.
27.
KumraSHerionDJacobsenLKBrigugliaCGrotheD.Case study: Risperidone-induced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiatry1997;36:701–5.
28.
KumraSJacobsenLLenaneMKarpBFrazierJSmithA, and others. Childhood-onset schizophrenia: An open-label study of olanzapine in adolescents. J Am Acad Child Adolesc Psychiatry1997. Forthcoming.
29.
ChouinardGJonesBRemingtonGBloomDAddingtonDMacEwanGW, and others. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and Haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol1993;13:25–40.
30.
MarderSRMeibachRC. Risperidone in the treatment of schizophrenia. Am J Psychiatry1994;151:825–35.
31.
BeasleyCMJrSangerTSatterleeWTollefsonGTranPHamiltonS.Olanzapine versus placebo: Results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology (Berl)1996;124:159–67.
32.
BeasleyCMJrTollefsonGTranPSatterleeWSangerTHamiltonS.Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology1996;14:111–23.
33.
TollefsonGDBeasleyCMJrTamuraRNTranPVPotvinJH. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry1997;154:1248–54.
34.
KaneJHonigfeldGSingerJMeltzerH.Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry1988;45:789–96.
35.
ChilesJA. Extrapyramidal reactions in adolescents treated with high-potency antipsychotics. Am J Psychiatry1978;135:239–40.
36.
KeepersGAClappisonVJCaseyDE. Initial anticholinergic prophylaxis for neuroleptic-induced extrapyramidal syndromes. Arch Gen Psychiatry1983;40:1113–7.
37.
TeicherMHGlodCA. Neuroleptic drugs: Indications and guidelines for their rational use in children and adolescents. J Child Adolesc Psychopharmacol1990;1:33–56.
38.
CaseyDE. Neuroleptic drug-induced extrapyramidal syndromes and tardive dyskinesia. Schizophr Res1991;4:109–20.
39.
WhitakerARaoU.Neuroleptics in pediatric psychiatry. Psychiatr Clin North Am1992;15:243–76.
40.
AguilarEJKeshavanMSMartinez-QuilesMDHernandezJGomez-BeneytoMSchoolerNR. Predictors of acute dystonia in first-episode psychotic patients. Am J Psychiatry1994;151:1819–21.
41.
CaseyD.Tardive dyskinesia. In: MeltzerHY, editor. Psychopharmacology: The third generation of progress. New York: Raven Press; 1987. p 1411–9.
42.
CampbellMGregaDMGreenWHBennettWG. Neuroleptic-induced dyskinesias in children. Clin Neuropharmacol1983;6:207–22.
43.
BaldessariniRJTeicherMH. Dosing of antipsychotic agents in pediatric populations [editorial]. J Child Adolesc Psychopharmacol1995;5:1–4.
44.
CampbellABaldessariniRJTeicherMH. Decreasing sensitivity to neuroleptic agents in developing rats; evidence for a pharmacodynamic factor. Psychopharmacology (Berl)1988;94:46–51.
45.
SeemanPBzowejNHGuanHCBergeronCBeckerLEReynoldsGP, and others. Human brain dopamine receptors in children and aging adults. Synapse1987;1:399–404.
46.
FindlingRLGrcevichSJLopezISchulzSC. Antipsychotic medications in children and adolescents. J Clin Psychiatry1996;57(9 Suppl):19S–23S.
47.
NordstromALFardeLWieselFAForslundKPauliSHalldinC, and others. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET study of schizophrenic patients. Biol Psychiatry1993;33:227–35.
48.
FardeLNordstromALWieselFAPauliSHalldinCSedvallG.Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry1992;49:538–44.
49.
KapurSRemingtonGJonesCWilsonADaSilvaJHouleS, and others. High levels of dopamine D2 receptor occupancy with low-dose haloperidol treatment: A PET study. Am J Psychiatry1996;153:948–50.
50.
WongDFWagnerHNJrDannalsRFLinksJMFrostJJRavertHT, and others. Effects of age on dopamine and serotonin receptors measured by positron tomography in the living human brain. Science1984;226:1393–6.
51.
IyoMYamasakiT.The detection of age-related decrease of dopamine D1, D2 and serotonin 5-HT2 receptors in living human brain. Prog Neuropsychopharmacol Biol Psychiatry1993;17:415–21.
52.
WangGJVolkowNDLoganJFowlerJSSchlyerDMacGregorRR, and others. Evaluation of age-related changes in serotonin 5-HT2 and dopamine D2 receptor availability in healthy human subjects. Life Sci1995;56(14):PL249–53.
53.
NordstromALFardeLNybergSKarlssonPHalldinCSedvallG.Di, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients. Am J Psychiatry1995;152:1444–9.
54.
KapurSRemingtonG.Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry1996;153:466–76.
55.
NybergSFardeLErikssonLHalldinCErikssonB.5-HT2 and D2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology1993;110:265–72.
56.
FardeLNybergSOxenstiernaGNakashimaYHalldinCEricssonB.Positron emission tomography studies on D-2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients. J Clin Psychopharmacol1995;15(1 Suppl):19S–23S.
57.
KapurSRemingtonGZipurskyRBWilsonAAHouleS.The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A PET study. Life Sci1995;57(10):PL103–7.
